Known hypersensitivity to -fluorouracil/leucovorin Known hypersensitivity to irinotecan Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs Patients with known hypersensitivity to any TZD oral agents are not eligible Known hypersensitivity to any oligodeoxynucleotide. Hypersensitivity to carboplatin or cisplatin Hypersensitivity to taxanes (such as Steven Johnson syndrome). Hypersensitivity, such as rash < Grade that is managed, is allowed. Patients with a known hypersensitivity to carboplatin Hypersensitivity to: Subjects with a hypersensitivity to sirolimus. Known hypersensitivity to one or more of the study agents used Known hypersensitivity to platinum compounds History of known hypersensitivity to cetuximab, docetaxel or similar agents Known hypersensitivity to the metal in the electrodes (stainless steel L) that cannot be medically managed Known hypersensitivity to methotrexate No known hypersensitivity to trastuzumab Patients with a known hypersensitivity to treosulfan and/or fludarabine Previously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalan The patient has known hypersensitivity to gelatin or lactose monohydrate Known hypersensitivity to the device constituent or TARIS Inserter materials. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product Known hypersensitivity to cetuximab or other EGFR antibody Has known hypersensitivity to baker's yeast Previously known hypersensitivity to any of the agents used in this study; known sensitivity to busulfan or fludarabine Documented hypersensitivity to bumetanide or sulfonamides Has hypersensitivity to nivolumab or any other drug used in this protocol Known hypersensitivity to one or more of the study agents Known hypersensitivity to any of the study agents used Known hypersensitivity to study drug and/or drug class Has a known hypersensitivity to any of the study therapy products Known hypersensitivity to any study drug used in this trial Known hypersensitivity to deferasirox Known hypersensitivity to any study drug Known hypersensitivity to either study drug (umbralisib or ibrutinib) Known hypersensitivity to S- or its metabolites (eg, -FU); Known hypersensitivity to one or more of the study agents Previously known hypersensitivity to any of the agents used in this study Previously known hypersensitivity to any of the agents used in this study Hypersensitivity to simvastatin or ezetimibe. Patients with known hypersensitivity to taxanes or platinums are to be excluded Known or possible hypersensitivity to palbociclib (CTCAE version [V] .) Subject has a known hypersensitivity to pembrolizumab or any of its ingredients Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to fluorouracil Patients with a known hypersensitivity to interferon-alpha Known hypersensitivity to -FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, Bravavir, etc.) Patients with known hypersensitivity to pegfilgrastim and filgrastim Known hypersensitivity to one or more of the study agents Hypersensitivity of TZD Known or suspected hypersensitivity to ruxolitinib. Previously known hypersensitivity to any of the agents used in this study Prior use of gossypol or AT-, or known hypersensitivity to gossypol or AT- Hypersensitivity to mithramycin Patients with a known hypersensitivity to any of the study agents Hypersensitivity to fluphenazine or other phenothiazines Hypersensitivity to any reagents used in the study. Known hypersensitivity to any study drug Known hypersensitivity to enzalutamide Known hypersensitivity to any of the study agents Hypersensitivity to acetazolamide or sulfonamides Known hypersensitivity to arsenic trioxide Known hypersensitivity to Cremophor-based agents patient has known hypersensitivity to alpelisib, fulvestrant or letrozole No known hypersensitivity to Escherichia (E.) coli-derived products TREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomide Hypersensitivity to mithramycin Known hypersensitivity to cetuximab or other EGFR antibody Known hypersensitivity to inactive ingredient of bevacizumab Known hypersensitivity to inactive ingredient of TPI Known hypersensitivity to any of the study agents used Hypersensitivity to any of the study medications Patients with known hypersensitivity to temozolomide or dacarbazine are not eligible With known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate) Patients who have hypersensitivity to sitagliptin Documented hypersensitivity to clobetasol Must not have known hypersensitivity to -aminoquinoline compound Patients with a known hypersensitivity to BKM, RAD (including other rapalogs) or their excipient Hypersensitivity to interferon alfa Suspected hypersensitivity to IFN alfab Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity). Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides. Known history of immunogenicity or hypersensitivity to a CD antibody. Known hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trial Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin Hypersensitivity or prior treatment with obinutuzumab Known hypersensitivity to the study treatment or any of its ingredients. Known history of immunogenicity or hypersensitivity to a CD antibody. Known hypersensitivity to -fluorouracil/leucovorin Known hypersensitivity to irinotecan Prior treatment with or hypersensitivity to study drug or related compounds Known hypersensitivity to bicalutamide. Patients with known hypersensitivity to any TZD oral agents are not eligible Previously known hypersensitivity to any of the agents used in this study Known hypersensitivity to one or more of the study agents Known hypersensitivity to any study drug Previously known hypersensitivity to any of the agents used in this study Patients with known hypersensitivity to any oligodeoxynucleotide. Known hypersensitivity to enzalutamide or related compounds Known hypersensitivity to acyclovir or similar anti-viral drug Has a known hypersensitivity to any of the study therapy products Known hypersensitivity to ibrutinib Subject has a known hypersensitivity to platinum compounds. Known hypersensitivity to everolimus or bendamustine Known hypersensitivity to trial drug Subject has a known hypersensitivity to platinum compounds. Known hypersensitivity to -fluorouracil/leucovorin Known hypersensitivity to capecitabine Known hypersensitivity to irinotecan Known hypersensitivity to acyclovir or similar anti-viral drug Known hypersensitivity to pembrolizumab or another mAb. Known hypersensitivity to both allopurinol and rasburicase Known hypersensitivity reaction to mushroom products Patients with a known hypersensitivity to tacrolimus Known anaphylactic or severe hypersensitivity to dasatinib or crizotinib or their analogs No known hypersensitivity to -aminoquinoline compound Patients with hypersensitivity to any tetracyclines No known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocol The patient has known hypersensitivity to bovine proteins Hypersensitivity to acyclovir or similar anti-viral drug Known hypersensitivity to cetuximab or other EGFR antibody Known hypersensitivity to any of the study agents used Known hypersensitivity to any of the study agents Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymyxin B, streptomycin, phenoxyethanol, formaldehyde, aluminum hydroxide, yeast Known hypersensitivity to fluoropyrimidines or cisplatin. Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids. Prior treatment with or have known hypersensitivity to AL. b. Indication B- LMS: Prior treatment with or have known hypersensitivity to dacarbazine. c. Indication C - SS: Prior treatment with or have known hypersensitivity to dacarbazine. Has known hypersensitivity to baker's yeast Known hypersensitivity to sirolimus. History of Grade ? infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP, erlotinib or gefitinib. Known history of ? Grade hypersensitivity to a therapeutic antibody. Known hypersensitivity to any constituent of the study medication. Known hypersensitivity to -azacytidine\r\n* Prior treatment with -azacytidine is allowed Known hypersensitivity to dacarbazine (DTIC). Known hypersensitivity to any inactive ingredient of bevacizumab Known hypersensitivity to any inactive ingredient of TPI Known hypersensitivity to lithium or tretinoin Has a known hypersensitivity to baker's yeast or has an active yeast infection; Patients with hypersensitivity to amiodarone or NAC Hypersensitivity to obinutuzumab Subjects with porphyrias or known hypersensitivity to porphyrins No known hypersensitivity to trastuzumab or pertuzumab Known hypersensitivity to rosuvastatin Patients in the combination arms - known hypersensitivity to fulvestrant Known hypersensitivity to filgrastim, plerixafor, or Escherichia (E.) coli derived products Known hypersensitivity to any of the treatment ingredients. Known previous Grade - infusion related reactions with anti-EGFR mABs Have known hypersensitivity to platinum (Pt) compounds Hypersensitivity to recombinant human IL- Known hypersensitivity to Tween-, or human immunoglobulin Known hypersensitivity to study-assigned chemotherapy Known hypersensitivity to any study drug Known hypersensitivity to NSAIDs Known hypersensitivity to varenicline Suspected hypersensitivity to interferon alpha Known hypersensitivity to polymyxin B Hypersensitivity to trial medications Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors. Known hypersensitivity to ibrutinib or nivolumab Known hypersensitivity to sirolimus Known hypersensitivity to human albumin Have known hypersensitivity to pancuronium bromide, atracurium or cisatracurium, Have known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents, Have a known hypersensitivity to olanzapine or to phenothiazines Patients known to have hypersensitivity to dacarbazine (DTIC) are not eligible Known hypersensitivity to cold Hypersensitivity to pregabalin Hypersensitivity to ginseng Patients with known hypersensitivity to octreotide or somatostatin Known or suspected hypersensitivity to any of the constituents of the investigational product Patients with hypersensitivity to any tetracycline Any known hypersensitivity to dexmedetomidine Patients with hypersensitivity to tetracyclines Minocycline trial only: patients with hypersensitivity to any tetracyclines Patients with known hypersensitivity to sildenafil or other ingredients of sildenafil History of known latex hypersensitivity Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO) History of known latex hypersensitivity Known hypersensitivity to NAC Patients who have hypersensitivity to sitagliptin Known hypersensitivity to cyclophosphamide or any of its metabolites Known hypersensitivity to one or more of the study agents Has suspected or known hypersensitivity to ingredients of MK- (letermovir) formulations Subjects with a known hypersensitivity to calcitriol The patient has a known hypersensitivity to Lymphazurin or Lymphoseek Known hypersensitivity to polyethylene glycol (PEG) Known hypersensitivity to trastuzumab or pertuzumab Hypersensitivity or anaphylactic reaction to any somatostatin analog or to maytansinoids The subject has a known hypersensitivity to Isosulfan Blue Dye. Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug EXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug Known hypersensitivity to NSAIDs Patients with known hypersensitivity including anaphylaxis to trabectedin Known hypersensitivity to NSAIDs Hypersensitivity to Caphosol ingredients Known hypersensitivity to tartrazine, a dye used in the ensartinib mg capsule. Known history of immunogenicity or hypersensitivity to a CD antibody.